Biosimilar Information Wars: Draft Guidance Seeks To Clamp Down On Efforts To Hinder Uptake In The US

 
• By Derrick Gingery

The guidance states that promotion creating an impression that differences are clinically meaningful when the US FDA has said they are not could be judged misleading.

Advertising
The US FDA said in draft guidance that accurate information comparing a biosimilar and its reference could be considered misleading if offered in the wrong context. • Source: Shutterstock

More from Marketing & Advertising

More from Compliance